• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Abera Bioscience

9.00 SEK

+3.93 %

Less than 1K followers

ABERA

Spotlight Stock Market

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+3.93 %
+36.36 %
+50.00 %
+32.35 %
+32.35 %
+21.62 %
+80.36 %
-4.05 %
-18.55 %

Abera Bioscience is a Swedish biotechnology company that develops nasal vaccines based on a proprietary OMV-based platform technology. The company's focus is on nasal vaccines that provide immune responses in both mucosal and systemic areas. Abera develops vaccines against several respiratory infectious diseases, including pneumococci, influenza and pandemic preparedness, with projects in preclinical and planned clinical phases. The company was founded in 2012 and is headquartered in Uppsala.

Read more
Market cap
184.49M SEK
Turnover
147.4K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
All
Press releases
ShowingAll content types

Financial calendar
20/8
2026

Interim report Q2'26

17/11
2026

Interim report Q3'26

15/2
2027

Annual report '26

Press release2026-06-23 09:13

Abera Bioscience publicerar vetenskaplig artikel i Vaccine som visar starkt skydd av intranasal influensavaccinkandidat

Abera Bioscience
Regulatory press release2026-06-16 13:20

Abera Bioscience: CEPI förlänger stöd till Aberas utveckling av vaccinplattformen BERA

Abera Bioscience
Regulatory press release2026-06-10 15:10

Kommuniké från årsstämma i Abera Bioscience AB

Abera Bioscience

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release2026-06-08 08:54

Abera Bioscience slutför GMP-produktion och förbereder klinisk start för vaccinkandidaten Ab-01.12

Abera Bioscience
Regulatory press release2026-05-12 07:02

Abera Bioscience AB Delårsrapport Q1 2026

Abera Bioscience
Regulatory press release2026-05-11 08:39

Abera Bioscience AB offentliggör årsredovisning för 2025

Abera Bioscience
Regulatory press release2026-05-11 08:25

Kallelse till årsstämma i Abera Bioscience AB

Abera Bioscience
Press release2026-04-01 08:25

Abera Bioscience: Ny publikation i npj Vaccines ger viktig insikt i verkningsmekanismen för Aberas pneumokockvaccin Ab-01.12

Abera Bioscience
Press release2026-03-11 13:07

Abera Bioscience publicerar presentation från Aktiespararnas Stora Aktiedagarna

Abera Bioscience
Regulatory press release2026-02-12 08:30

Abera Bioscience AB Bokslutskommuniké 2025

Abera Bioscience
Press release2026-02-10 08:20

Abera Bioscience: Brev från Aberas nya storägare

Abera Bioscience
Regulatory press release2026-02-03 13:36

Abera Bioscience inleder nya studier inom pandemisk influensa - CEPI godkänner förlängning av projekt

Abera Bioscience
Regulatory press release2026-01-30 09:56

Abera Bioscience stärker kapitalbasen för accelererad utveckling och breddad pipeline

Abera Bioscience
Press release2026-01-27 13:26

Abera Bioscience publicerar presentation från Aktiespararnas life science event

Abera Bioscience
Press release2026-01-22 11:21

Abera Bioscience stärker teamet för att möta högt utvecklingstempo

Abera Bioscience
Press release2025-11-27 14:03

Abera Bioscience publicerar presentation från FS Markets investerarevent i Stockholm

Abera Bioscience
Regulatory press release2025-11-13 08:01

Abera Bioscience AB Delårsrapport Q3 2025

Abera Bioscience
Press release2025-11-04 08:30

Abera Bioscience: Artikel: Influensa och kampen mot framtida pandemier

Abera Bioscience
Press release2025-10-21 10:18

Abera Bioscience visar lovande långtidsdata för nasalt influensavaccin - starka och långvariga immunsvar i ny preklinisk studie

Abera Bioscience
Regulatory press release2025-09-29 14:35

Abera Bioscience tilldelas ca 880 000 SEK i bidrag från BactiVac för studier på sprayapplikator inför kliniska prövningar av pneumokockvaccin Ab-01.12

Abera Bioscience